PLK1 and non-small cell lung carcinoma: To find pathways that can drive Plk1 inhibitor resistance, we examined data for all NSCLC cell lines from two sources: (i) protein and phosphoprotein expression measured using reverse phase protein array (RPPA) from the MD Anderson Cell Line Project database (Li et al, 2017), and (ii) Plk1 inhibitor sensitivity from the Cancer Therapeutics Response Portal v2 (CTRPv2; https://portals.broadinstitute.org/ctrp/) database (Seashore‐Ludlow et al, 2015).